Cancer Biology and Cancer Stem Cells

项目摘要 癌症生物学和癌症干细胞（CB）计划是一个基础和转化科学计划，旨在 了解癌症发展的基本机制。从这些见解中，我们渴望 通过以下具体目标改善癌症诊断和治疗：（1）了解法规， 正常和癌症干细胞的功能，（2）了解启动和发展的机制， 上皮癌，和（3）确定潜在的新的治疗靶点。 该计划由Laura Attardi博士和Roeland Nusse博士共同领导。2019年，前癌症生物学 计划和癌症干细胞计划合并EAB的批准，成为目前的癌症 生物学和癌症干细胞计划。在目前的资助期间，项目成员已经取得了实质性的进展， 了解癌症干细胞自我更新途径和阐明信号通路的进展 与癌症高度相关，包括最突出的Wnt和Hedgehog途径。他们还 开创了一项新技术，ATAC-seq，使人们能够更根本地了解染色质的作用， 并使用类器官和小鼠模型系统来发现肿瘤的机制 抑制剂和进展，并发现新的治疗靶点。当前计划的53名成员 代表医学院（SOM），人文科学和工程学院的16个部门。 成员得到同行评审研究的支持，总额为2560万美元，包括34个R 01，12个R35，6个U 01， 三架T32同行评审的癌症研究资金包括来自NCI的700万美元，来自其他NIH的1200万美元 来自其他同行评审来源的660万美元。这个项目的成员都很积极， 他们的目标是使用基础科学方法来了解癌症的发生和发展， 提高癌症诊断和治疗的最终目的。自2015年以来，CB计划的成员 出版了668份手稿。其中，16%为方案内，31%为方案间， 在95%的多机构合作中，43%和33%分别发表在IF>10和IF>20的期刊上。的 斯坦福大学癌症研究所（SCI）通过提供最先进的共享资源， 对新项目的种子赠款支持，计划资金，务虚会，特别研讨会，对新教师的支持 招聘和临床试验基础设施，用于翻译研究结果。SCI的支持 还通过组织各种活动，促进方案内和方案间的合作， 方案和工作组会议，并提供与更注重临床的 计划，以提高我们的翻译影响力。未来的计划包括进一步加强内部和内部， 通过加强癌症重点工作组的项目合作。

PROJECT SUMMARY The Cancer Biology and Cancer Stem Cells (CB) Program is a basic and translational science program that aims to understand the fundamental mechanisms underlying cancer development. From these insights, we aspire to improve cancer diagnosis and treatment through the following specific aims: (1) understand the regulation and function of normal and cancer stem cells, (2) understand the mechanisms of initiation and progression of epithelial cancers, and (3) identify potential new therapeutic targets. The program is co-led by Laura Attardi, PhD, and Roeland Nusse, PhD. In 2019, the former Cancer Biology Program and Cancer Stem Cells Program merged with the approval of the EAB to become the current Cancer Biology and Cancer Stem Cells Program. In the current funding period, program members have made substantial progress in understanding the self-renewal pathways of cancer stem cells and in elucidating signaling pathways of high cancer relevance, including most prominently the Wnt and Hedgehog pathways. They have also pioneered a new technology, ATAC-seq, that enables a more fundamental understanding of the role of chromatin in gene expression and used organoid and mouse model systems to discover the mechanisms of tumor suppressors and progression and to uncover new therapeutic targets. The 53 members of the current program represent 16 departments within the Schools of Medicine (SOM), Humanities and Sciences, and Engineering. Members are supported by peer-reviewed research totaling $25.6M, including 34 R01s, 12 R35s, 6 U01s, and 3 T32s. Peer-reviewed cancer-focused research funding consists of $7M from the NCI, $12M from other NIH sources, and $6.6M from other peer-reviewed sources. The members of this program are highly motivated and interactive in their goal to use basic science approaches to understand cancer initiation and progression, with the ultimate aim of improving cancer diagnosis and treatment. Since 2015, members of the CB Program have published 668 manuscripts. Of these, 16% represent intra-programmatic, 31% represent inter-programmatic, and 95% multi-institutional collaborations, 43% and 33% are in journals with IF>10 and IF>20, respectively. The Stanford Cancer Institute (SCI) enhances the program’s goals by providing state-of-the-art shared resources, seed grant support for new projects, programmatic funds, retreats, special seminars, support for new faculty recruitments, and clinical trial infrastructure for translation of research findings. The support from the SCI has also been instrumental in promoting both intra- and inter-programmatic collaborations through organizing programmatic and working group meetings and providing the means to interface with the more clinically oriented programs to enhance our translational impact. Future plans incluce to further enhance intra- and inter- progammtic collaborations by enhance cancer focused working groups.